Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study found that systemic mycophenolate mofetil and topical clobetasol were equally effective at reducing lichen planopilaris activity over six months, but satisfaction differed between the treatments.

In this study, two patients with refractory juvenile dermatomyositis improved clinically and in disease activity after receiving the JAK inhibitor tofacitinib, showing potential effects in managing the condition.

This study found that azelaic acid at all tested concentrations showed anti-Demodex efficacy similar to 5% permethrin, with no statistically significant differences between the treatments.

This study reported that dupilumab successfully induced remission of chronic, disseminated eczema herpeticum in a six-year-old girl with DOCK8-deficiency hyper-IgE syndrome, achieving complete resolution of herpetic lesions and significant skin, hair, and nail improvement within three months.

This case report details a 46-year-old woman with severe atopic dermatitis and alopecia areata universalis who experienced renewed hair growth and improved skin symptoms after starting dupilumab therapy.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

This study found that GLP-1 receptor agonists show potential for improving psoriasis and hidradenitis suppurativa by reducing inflammation and lesion severity, but they also pose dermatological risks such as alopecia and injection site reactions.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

This systematic review reports promising efficacy and safety of Tofacitinib for treating Alopecia Areata in children, though further randomized studies are needed due to the low quality of existing evidence.

Adalimumab improved folliculitis decalvans in most patients.

In this study, researchers prepared a humanized CXCL12 antibody for alopecia areata treatment, finding it significantly delayed disease onset in mice and reduced immune cell activation, suggesting potential as an immune modulatory therapy.

This case report describes a young woman with ankylosing spondylitis who developed a severe paradoxical skin reaction after six months on certolizumab, requiring treatment with secukinumab and methotrexate.

This case report describes a 21-year-old woman with progressive alopecia areata who experienced hair regrowth while treated with tocilizumab for posterior uveitis, suggesting the potential for this drug to affect hair loss and regrowth by disrupting interleukin-6 signaling.

This case study reports a 70-year-old man with treatment-resistant pityriasis rubra pilaris achieving complete clinical remission with ustekinumab, adding to evidence supporting biologic therapy when TNF inhibitors are unsuitable.

OR101 may effectively treat atopic dermatitis and similar skin conditions.

In this study, Mpzl3-/- mice developed severe seborrhea-like dermatitis with skin inflammation, indicating MPZL3's role in the skin condition's development, independent of adaptive immunity.

This study observed that the choice between using Belimumab and Anifrolumab for treating active Systemic Lupus Erythematosus was mainly based on clinical phenotype, with Anifrolumab linked to chronic-active disease and Belimumab associated with relapsing-remitting disease.

This report describes a case of hypozincemia type-II in an exclusively breast-fed infant, which resolved with zinc therapy and weaning, highlighting genetic factors in zinc transporter gene SLC30A2.

Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.

This case report describes a patient with psoriasis, vitiligo, and alopecia areata who showed significant improvement in all conditions after treatment with ustekinumab, suggesting potential benefits of IL-12/23 blockade for these autoimmune diseases.

This study found that anifrolumab effectively reduced disease activity and allowed for corticosteroid tapering in patients with systemic lupus erythematosus at Kanazawa University Hospital.

This review summarizes updated US prescribing information for teriflunomide in relapsing multiple sclerosis, highlighting its efficacy in reducing lesion activity and relapse rates but noting potential adverse effects such as headache and diarrhea.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This study reports a case where a biologic medication used for atopic dermatitis unexpectedly also treated concurrent alopecia areata.

In this case report, combination therapy effectively resolved chronic malasseziosis within 28 days in a small-breed dog from a Southeast Asian tropical climate, with significant symptom improvement and reduced Malassezia density observed by week 4.

In this study, the choice between Belimumab and Anifrolumab for treating Systemic Lupus Erythematosus was mainly influenced by the clinical features of the disease, such as chronic-active or relapsing-remitting courses and specific manifestations like cutaneous involvement or arthritis.

This study reports that anifrolumab showed promising improvement in a case of refractory discoid lupus erythematosus, specifically enhancing skin lesions and promoting hair regrowth, suggesting potential as an effective therapy for severe cases.

This case report describes a 69-year-old woman who developed drug-induced acquired ichthyosis related to ponatinib therapy, which improved upon stopping the medication.

This source reports that four weeks of dupilumab treatment led to notable improvement in skin lesions, including multiple erythematous patches and papules on the face, back, and limbs.